#Eylea

[bidhuan]

FDA Menyetujui Biosimilars Pertama untuk Eylea

Majalah Farmasetika – Aflibercept-jbvf (Yesafili; Biocon Biologics) dan aflibercept-yszy (Opuviz; Biogen, Samsung Bioepis) merupakan biosimilars pertama yang dapat dipertukarkan dengan aflibercept (Eylea; Regeneron). FDA menyetujui aflibercept-jbvf (Yesafili; Biocon Biologics) dan aflibercept-yszy (Opuviz; Biogen, Samsung Bioepis), biosimilars pertama yang dapat dipertukarkan dengan aflibercept…

[newsmarketreports]

Navigating Challenges: Bayer's Financial Strategies for Growth

Bayer AG, headquartered in Leverkusen, Germany, is a global leader in the life sciences industry, with a diverse portfolio spanning pharmaceuticals, consumer health, and agricultural products. As a major player in the global market, Bayer’s financial performance is closely watched by investors, stakeholders, and analysts alike. This article provides a comprehensive financial analysis of Bayer AG, highlighting its revenue streams, expenditure patterns, key financial ratios, and future strategic outlook.

To know about the assumptions considered for the study, Download for Free Sample Report

Revenue Streams: A Balanced and Diversified Portfolio

Bayer AG’s revenue is driven by a well-diversified portfolio of products and services across multiple segments. The primary revenue streams include:

Pharmaceuticals: The pharmaceuticals segment is a significant contributor to Bayer’s revenue, driven by its portfolio of prescription medicines. These include treatments for cardiovascular diseases, oncology, women’s health, and hematology. Blockbuster drugs such as Xarelto (anticoagulant) and Eylea (ophthalmology) have been particularly strong performers, contributing substantially to Bayer’s top line.

Consumer Health: Bayer’s consumer health division offers over-the-counter (OTC) products, including analgesics, allergy relief, vitamins, and skincare products. Brands like Aspirin, Claritin, and Bepanthen are household names that contribute to consistent revenue from this segment, making it a key pillar of Bayer’s business.

Crop Science: The crop science division, bolstered by Bayer’s acquisition of Monsanto in 2018, is another major revenue driver. This segment includes seeds, crop protection products, and digital farming solutions. Bayer’s leadership in agricultural innovations, particularly in herbicides and genetically modified seeds, has positioned it as a dominant player in this market.

Animal Health: Although Bayer sold its animal health division in 2020, this segment previously contributed to the company’s revenue through veterinary products and services. The divestiture was part of Bayer’s strategy to streamline operations and focus on core business areas.

Expenditure Management: Strategic Investments and Cost Efficiency

Bayer AG’s expenditure management is focused on balancing strategic investments with cost efficiency. Key areas of spending include:

Research and Development (R&D): R&D is a critical area of expenditure for Bayer, particularly in the pharmaceuticals and crop science segments. The company allocates a significant portion of its budget to developing new drugs, agricultural products, and innovative technologies. This investment is essential for maintaining Bayer’s competitive edge and driving future growth.

Manufacturing and Supply Chain: Bayer invests heavily in its manufacturing facilities and supply chain operations. The company’s global footprint requires a well-coordinated supply chain to ensure timely production and delivery of its products. Bayer’s focus on operational efficiency helps minimize costs while maintaining high-quality standards.

Marketing and Sales: A substantial portion of Bayer’s expenditure goes towards marketing and sales activities. The company employs strategic marketing campaigns to promote its products, particularly in the consumer health and pharmaceuticals segments. These efforts are crucial for maintaining brand recognition and driving product demand.

Legal and Compliance Costs: Bayer faces significant legal and compliance costs, particularly related to its crop science division. The acquisition of Monsanto brought with it a series of legal challenges, particularly related to glyphosate-based products. Managing these costs is crucial for protecting Bayer’s financial health and reputation.

Key Financial Ratios: Evaluating Bayer’s Financial Health

Analyzing Bayer AG’s key financial ratios provides insights into its operational efficiency, profitability, and overall financial stability:

Gross Profit Margin: The gross profit margin reflects the efficiency of Bayer in managing its production costs relative to its sales. A high gross margin indicates that Bayer is effectively controlling its cost of goods sold (COGS), which is critical for maintaining profitability across its diverse product lines.

Operating Margin: The operating margin measures the efficiency of Bayer’s core business operations by comparing operating income to net sales. Bayer’s operating margin is an important indicator of its ability to generate profit from its primary activities, excluding the impact of taxes and interest expenses.

Return on Equity (ROE): ROE measures the profitability of Bayer in relation to shareholders’ equity. A strong ROE indicates that Bayer is effectively using shareholders’ funds to generate profits, reflecting sound financial management and strategic investment decisions.

Debt-to-Equity Ratio: This ratio compares Bayer’s total liabilities to its shareholders’ equity, indicating the extent to which the company is financing its operations through debt. A lower debt-to-equity ratio suggests a more conservative approach to leveraging, reducing financial risk and enhancing long-term stability.

Future Strategic Outlook: Growth Opportunities and Challenges

Bayer AG’s future outlook is shaped by its strategic initiatives, which aim to capitalize on growth opportunities while addressing ongoing challenges:

Innovation in Pharmaceuticals: Bayer is focusing on expanding its pharmaceutical pipeline with new treatments for unmet medical needs. The company’s investment in gene therapy, oncology, and cardiovascular diseases is expected to drive future growth. Bayer’s focus on innovation is key to sustaining its leadership in the highly competitive pharmaceutical industry.

Sustainability in Agriculture: As part of its commitment to sustainability, Bayer is investing in environmentally friendly agricultural solutions. This includes developing crop protection products with reduced environmental impact and promoting digital farming technologies. Bayer’s leadership in sustainable agriculture positions it well to meet the growing demand for eco-friendly farming practices.

Regulatory and Legal Challenges: Bayer continues to navigate complex regulatory and legal landscapes, particularly in its crop science division. The ongoing litigation related to glyphosate and other products poses financial and reputational risks. Successfully managing these challenges will be crucial for Bayer’s long-term success.

Expansion in Emerging Markets: Bayer is targeting growth in emerging markets, where demand for pharmaceuticals and agricultural products is rising. The company’s strategic focus on expanding its presence in Asia, Latin America, and Africa is expected to drive future revenue growth and diversify its market base.

Conclusion

Bayer AG’s financial performance reflects its strong position in the global life sciences industry. With a diversified revenue base, strategic investments in R&D, and a focus on innovation, Bayer is well-equipped to navigate future challenges and capitalize on growth opportunities. As the industry evolves, Bayer’s commitment to sustainability, innovation, and operational efficiency will be critical to its continued success.

[eyeqindia903]

AMDAge-Related Macular Degeneration (AMD): Symptoms, Diagnosis & Treatment

Age-Related Macular Degeneration (AMD) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the center of the visual field. EyeQ India, a leading eye care provider, offers comprehensive services for the diagnosis and treatment of AMD. This article discusses the symptoms, diagnostic methods, and treatment options for AMD as provided by EyeQ India.

Symptoms of Age-Related Macular Degeneration

Age-Related Macular Degeneration (AMD) progresses through different stages, and symptoms can vary depending on the severity and type of AMD. Common symptoms include:

Blurriness in Central Vision: Initial stages often cause a slight blurriness in the center of vision, which can gradually worsen.

Difficulty in Reading and Recognizing Faces: As central vision deteriorates, recognizing faces and reading small print becomes challenging.

Distorted Vision: Straight lines may appear wavy or bent, indicating potential macular damage.

Dark or Empty Areas in Vision: Advanced AMD can cause dark or empty spots in the central visual field.

Reduced Color Perception: Colors may appear less vivid, making daily tasks difficult.

Types of AMD

Dry AMD: The most common type, characterized by the thinning of the macula and gradual vision loss.

Wet AMD: Less common but more severe, involving abnormal blood vessel growth under the retina, leading to rapid vision loss.

Diagnosis of AMD

EyeQ India employs advanced diagnostic techniques to accurately detect and assess AMD:

Comprehensive Eye Exam: A detailed eye examination to check for signs of AMD and assess overall eye health.

Visual Acuity Test: Measures the clarity of vision and detects any vision loss.

Amsler Grid Test: Identifies any distortions in the central visual field.

Optical Coherence Tomography (OCT): An imaging test that provides detailed cross-sectional images of the retina, helping to detect macular thinning or fluid accumulation.

Fluorescein Angiography: A diagnostic procedure where a dye is injected into the bloodstream to highlight abnormal blood vessels in the retina.

Treatment Options for AMD

EyeQ India offers a range of treatment options tailored to the type and severity of AMD:

Lifestyle and Dietary Changes:

Nutritional Supplements: High-dose vitamins and minerals, such as the AREDS2 formula, can slow the progression of AMD.

Healthy Diet: A diet rich in leafy greens, fish, and nuts supports overall eye health.

Medications:

Anti-VEGF Injections: For wet AMD, medications like Avastin, Lucentis, and Eylea are injected into the eye to inhibit abnormal blood vessel growth and reduce fluid leakage.

Photodynamic Therapy (PDT): Involves the use of a light-activated drug to destroy abnormal blood vessels.

Laser Therapy:

Laser Photocoagulation: A laser is used to seal off abnormal blood vessels, primarily in cases of wet AMD.

Low Vision Aids:

Devices such as magnifying glasses, special lenses, and electronic aids can help individuals with AMD manage daily activities.

Surgical Options:

In advanced cases, surgical interventions may be considered to improve vision or manage complications.

Preventive Measures and Ongoing Care

Preventive measures and regular follow-up care are crucial for managing AMD:

Regular Eye Check-Ups: Frequent visits to the ophthalmologist for monitoring and early detection of AMD progression.

Protective Eyewear: Wearing sunglasses to protect the eyes from harmful UV rays.

Healthy Lifestyle Choices: Quitting smoking, maintaining a healthy weight, and managing blood pressure and cholesterol levels.

Conclusion

Age-Related Macular Degeneration is a serious condition that can significantly impact quality of life. However, with early detection and appropriate treatment, the progression of AMD can be slowed, and vision loss can be managed effectively. EyeQ India is dedicated to providing comprehensive care for AMD patients, ensuring they receive the best possible support and treatment to maintain their vision and quality of life.

[vexedallay]

Eylea! Sedu norifafi osit !

(hello! You are good! :] )

working on stuff so that’s about all I have right now that isn’t saying you’re the stars or sky or running pfft- conlang stuff!

!!! That's so cool! I love conlangs so much

The one I'm working on currently has no actual words lol, I've decided to start w/ grammar and things so uh...

[spookysaladchaos]

Aflibercept Biosimilars, Global Market Size Forecast, Top 4 Players Rank and Market Share

Aflibercept Biosimilars Market Summary

According to the new market research report “Global Aflibercept Biosimilars Market Report 2023-2029”, published by QYResearch, the global Aflibercept Biosimilars market size is projected to reach USD 10.4 billion by 2029, at a CAGR of 1.4% during the forecast period.

Figure.   Global Aflibercept Biosimilars Market Size (US$ Million), 2018-2029

Above data is based on report from QYResearch: Global Aflibercept Biosimilars Market Report 2023-2029 (published in 2023). If you need the latest data, plaese contact QYResearch.

Figure.   Global Aflibercept Biosimilars Top 4 Players Ranking and Market Share (Ranking is based on the revenue of 2022, continually updated)

Above data is based on report from QYResearch: Global Aflibercept Biosimilars Market Report 2023-2029 (published in 2023). If you need the latest data, plaese contact QYResearch.

According to QYResearch Top Players Research Center, the global key manufacturers of Aflibercept Biosimilars include Regeneron Pharmaceuticals, Bayer HealthCare, etc. In 2022, the global top three players had a share approximately 100.0% in terms of revenue.

Figure.   Aflibercept Biosimilars, Global Market Size, Split by Product Segment

Based on or includes research from QYResearch: Global Aflibercept Biosimilars Market Report 2023-2029.

In terms of product type, currently 2mg is the largest segment, hold a share of 100.0%.

Figure.   Aflibercept Biosimilars, Global Market Size, Split by Application Segment

Based on or includes research from QYResearch: Global Aflibercept Biosimilars Market Report 2023-2029.

In terms of product application, currently Hospitals is the largest segment, hold a share of 71.1%.

Figure.   Aflibercept Biosimilars, Global Market Size, Split by Region

Based on or includes research from QYResearch: Global Aflibercept Biosimilars Market Report 2023-2029.

Market Drivers:

Clinical Innovation and Advancements: Ongoing research and development, as well as innovations in the formulation or delivery of Eylea, can drive market growth. Advancements that improve treatment outcomes, reduce dosing frequency, or enhance patient convenience may positively impact the market;

Increase In the Number of Sick People: The prevalence of eye conditions such as AMD and DME, coupled with an aging population, contributes to the demand for effective treatments. Global demographic trends and an increasing burden of eye diseases can drive the market for Eylea;

Expanded Indications: Obtaining additional approvals for new indications can significantly expand the market for Eylea. As clinical trials demonstrate the drug's effectiveness in treating different eye conditions, regulatory approvals for these new indications can drive increased usage.

Restraint:

Patent restrictions become an important factor in entering the market;

The leading enterprises have a high degree of concentration, complete products and great competitive advantages;

Economic downturns and budget constraints within healthcare systems may impact the affordability and reimbursement of Eylea. Changes in economic conditions can influence the overall market for pharmaceuticals.

Opportunity:

Advancements in medical technology: Ongoing advancements in medical technology are expected to broaden the application of biosimilars in the treatment of cancer and eye diseases;

Increased treatment options for patients: The entry of Aflibercept biosimilars into the market will provide patients with more treatment options and the potential to reduce medical costs, presenting growth opportunities for the market.

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

[opticalhub]

Diabetic Retinopathy: Protect Your Vision

Diabetic Retinopathy: Protect Your Vision

Diabetes, a condition that affects millions worldwide, has profound implications for overall health, and the eyes are no exception. One of the most serious ocular complications of diabetes is diabetic retinopathy, a condition that damages the blood vessels in the retina and can lead to irreversible vision loss. For those with diabetes, safeguarding against the unseen dangers of diabetic retinopathy is crucial for maintaining good vision and quality of life. This guide will lay the foundation for understanding diabetic retinopathy and offer strategies to manage it effectively.

Understanding Diabetic RetinopathyDiabetic retinopathy emerges from prolonged high blood sugar levels, which cause havoc in the retinal blood vessels. As damage progresses, these vessels can swell, leak, or close, preventing blood from passing through. In advanced cases, abnormal new blood vessels can grow on the surface of the retina, which can lead to further complications.The Stages of Diabetic RetinopathyDiabetic retinopathy generally evolves through four stages:- Mild Nonproliferative Retinopathy: Microaneurysms occur, which are small areas of balloon-like swelling in the retina's blood vessels. - Moderate Nonproliferative Retinopathy: Blood vessels that nourish the retina may swell and distort. They may also lose their ability to transport blood. - Severe Nonproliferative Retinopathy: More blood vessels become blocked, depriving several areas of the retina of their blood supply. - Proliferative Retinopathy: The retina starts growing new blood vessels, which are often fragile and can lead to serious vision problems if they leak blood. - Blurry or fluctuating vision - Dark or empty areas in your vision - Difficulty with color perception - Seeing spots or floaters - Vision lossThese symptoms may not necessarily indicate the presence of retinopathy alone, so a comprehensive diagnosis by a healthcare professional is paramount.

Risk Factors: More Than Just DiabetesWhile every person with diabetes faces the risk of developing diabetic retinopathy, there are additional risk factors:- Poor control of blood sugar levels - High blood pressure and cholesterol - Prolonged duration of diabetes - Smoking - Being African American, Hispanic, or Native American - Visual acuity testing - Tonometry (eye pressure testing) - Optical coherence tomography (OCT) - Fluorescein angiography, to examine the blood flow in the retinaAnnual eye exams for people with diabetes are strongly recommended, as early detection and treatment can limit the potential for significant vision loss. Previous Next shop now Treatment: Taking ActionDepending on the severity, various treatments are available for diabetic retinopathy:Early Stages- Managing blood sugar, blood pressure, and cholesterol is often the recommended treatment. - Medications that help control blood sugar, as well as a healthy diet and regular exercise, are part of early intervention. - Focal or grid laser treatment (photocoagulation): Can stop or slow the leakage of blood and fluid from vessels in the eye. - Panretinal laser treatment (scatter laser treatment): Can shrink abnormal blood vessels. - Vitrectomy: A surgical procedure that removes the vitreous gel and blood from leaking vessels in the back of the eye. - Anti-VEGF Injection Therapy: Medications like Lucentis, Eylea, or Avastin injected into the eye, which can prevent new blood vessels from forming and decrease vessel permeability.

Image source: Harward Health Publishing Managing Life with Diabetic RetinopathyWhile the implications of diabetic retinopathy on vision can be daunting, there is much you can do to contribute to the successful management of the condition:- Monitor your blood sugar levels meticulously. - Maintain an A1C that's as close to normal as possible. - Keep your blood pressure and cholesterol in check. - Stay active, exercise regularly, and maintain a healthy weight. - Quit smoking or seek support to stop. - Stay vigilant about scheduling and keeping eye appointments. - Communicate with your healthcare provider about any shifts in your vision. - Non-invasive imaging tests are improving the accuracy of diagnoses. - Novel pharmacological treatments are being developed to provide more effective treatment options. - Telemedicine and AI are expanding access to diabetic eye screening, even in remote areas. Previous Next sHOP NOW Being Proactive: Education and AdvocacyOne of the most potent tools in battling diabetic retinopathy is knowledge. Educate yourself about diabetes and eye health. Advocacy for regular eye care, and early intervention can make a monumental difference.Lifestyle as Medicine: The Holistic ApproachA holistic approach that encompasses diet, exercise, and healthy living can go far beyond treating diabetic retinopathy. It can enhance overall health, potentially reducing the diabetes complications that could lead to eye problems.

Diabethic Retinopathy: Vision and DiligenceProtecting your vision from the unseen dangers of diabetic retinopathy involves a commitment to routine eye care, vigilant health management, and a proactive partnership with health professionals. Taking such steps will not only help safeguard your eyes but can also contribute to a better quality of life.Our online optician store is dedicated to supporting individuals managing diabetic retinopathy, offering products and resources to help maintain optimal eye health.Embrace your eye health journey with our support.Managing diabetic retinopathy effectively can seem like an uphill battle, but with the correct knowledge and resources, it becomes a journey filled with hope for maintaining and protecting your vision. Shop now Facebook Youtube Instagram Pinterest Twitter Linkedin Wordpress Read the full article

[drdavidgoh]

Advance Age Related Macular Degeneration Treatments 2024

Macular degeneration, also known as age-related macular degeneration (AMD), is a common eye condition and a leading cause of vision loss among people over 50. It affects the macula, a small spot near the centre of the retina that is responsible for sharp, central vision.

In Singapore, like in many other countries, Age related macular degeneration(AMD) is a significant concern due to its impact on vision and quality of life for older adults. Treatment options for AMD vary depending on the type and severity of the condition. Some common treatments include:

Anti-VEGF Injections: Drugs such as ranibizumab (Lucentis), bevacizumab (Avastin), and aflibercept (Eylea) can be injected into the eye to inhibit the growth of abnormal blood vessels that contribute to AMD.

Photodynamic Therapy (PDT): This involves using a light-sensitive drug (verteporfin) combined with a special laser to selectively destroy abnormal blood vessels in the eye.

Laser Therapy: Certain types of AMD, such as certain cases of neovascular AMD, may be treated with laser therapy to seal leaking blood vessels.

Low Vision Aids: For individuals with advanced AMD and significant vision loss, low vision aids such as magnifiers, telescopic lenses, and electronic magnification devices can help maximize remaining vision.

Nutritional Supplements: Some studies suggest that certain nutritional supplements, particularly those containing antioxidants and zinc, may help slow the progression of AMD in some cases. These supplements typically include vitamins C and E, beta-carotene, zinc, and copper.

It's important for individuals with AMD to undergo regular eye exams to monitor the progression of the condition and to discuss treatment options with their eye care professionals. Additionally, lifestyle factors such as maintaining a healthy diet, not smoking, and protecting the eyes from harmful UV light may help reduce the risk of AMD progression. For specific information on AMD treatment options and resources available in Singapore, individuals should consult with local eye care professionals or organizations specializing in vision health.

[lalsingh228-blog]

Age Related Macular Degeneration Market Projected to Show Strong Growth

Worldwide Age Related Macular Degeneration Market In-depth Research Report 2023, Forecast to 2028 is latest research study released by AMA evaluating the market risk side analysis, highlighting opportunities and leveraged with strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Worldwide Age Related Macular Degeneration Market. Some of the key players profiled in the study are Novartis Ag (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Pfizer Inc. (United States), Regeneron Pharmaceutical, Inc. (United States), Acucela (United States), Neurotech Pharmaceuticals, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Santen Pharmaceutical Co. Ltd. (Japan), Synthetic Biologics Inc. (United States) Get Free Access to Sample Report @ https://www.advancemarketanalytics.com/sample-report/37693-global-age-related-macular-degeneration-market

The age-related macular degeneration (AMD) is a common eye complaint and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a minor spot near the center of the retina and the portion of the eye needed for sharp, central vision, which lets a person see objects that are straight ahead. In some people, AMD develops so slowly that vision loss does not occur for a long time. In others, the disease advancements faster and may lead to a loss of vision in one or both eyes. As AMD progresses, a blurred area near the center of vision is a general symptom.

Influencing Market Trend

Increasing Awareness about Age-Related Macular Degeneration

Market Drivers

Increase in Aging Population Worldwide

Rising Pipeline Drugs for Age-Related Macular Degeneration

Opportunities:

Increasing Incidence of Lifestyle Associated Diseases

Challenges:

Growing Off Label Use

For more data or any query mail at sales@advancemarketanalytics.comEnquire for customization in Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/37693-global-age-related-macular-degeneration-market

Furthermore, the years considered for the study are as follows: Historical year – 2017-2021 Base year – 2021 Forecast period** – 2022 to 2027 [** unless otherwise stated] Highlighted of Global Age Related Macular Degeneration Market Segments and Sub-Segment: Market by Key Players: Novartis Ag (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Pfizer Inc. (United States), Regeneron Pharmaceutical, Inc. (United States), Acucela (United States), Neurotech Pharmaceuticals, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Santen Pharmaceutical Co. Ltd. (Japan), Synthetic Biologics Inc. (United States)Market by: by Type (Wet AMD, Dry AMD), Drugs (Lucentis, Eylea, Avastin, Others), Route of Administration (Intravenous, Intravitreal)

Regional Analysis for Worldwide Age Related Macular Degeneration Market:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

• North America (U.S., Canada, and Mexico)

• South America (Brazil, Chile, Argentina, Rest of South America)

• MEA (Saudi Arabia, UAE, South Africa)The study is a source of reliable data on: Market segments and sub-segments, Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological innovations Value chain and investor analysis. Buy the Full Research report of Global Age Related Macular Degeneration Market@: https://www.advancemarketanalytics.com/buy-now?format=1&report=37693 Key Growths in the Market: This section of the report incorporates the essential enhancements of the marker that contains assertions, coordinated efforts, R&D, new item dispatch, joint ventures, and associations of leading participants working in the market.Key Points in the Market: The key features of this Age Related Macular Degeneration market report includes production, production rate, revenue, price, cost, market share, capacity, capacity utilization rate, import/export, supply/demand, and gross margin. Key market dynamics plus market segments and sub-segments are covered. FIVE FORCES & PESTLE ANALYSIS:

In order to better understand market conditions five forces analysis is conducted that includes the Bargaining power of buyers, Bargaining power of suppliers, Threat of new entrants, Threat of substitutes, and Threat of rivalry.

• Political (Political policy and stability as well as trade, fiscal, and taxation policies)

• Economical (Interest rates, employment or unemployment rates, raw material costs, and foreign exchange rates)

• Social (Changing family demographics, education levels, cultural trends, attitude changes, and changes in lifestyles)

• Technological (Changes in digital or mobile technology, automation, research, and development)

• Legal (Employment legislation, consumer law, health, and safety, international as well as trade regulation and restrictions)

• Environmental (Climate, recycling procedures, carbon footprint, waste disposal, and sustainability)

Examine Detailed Index of full Research Study at@: https://www.advancemarketanalytics.com/reports/37693-global-age-related-macular-degeneration-market Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[empressxmachina]

"Burn Break," a photo-manipulation by me (also on DA)

I think I first found this base picture at least four years ago, knowing that I had to use it for Tyler one day, but the right inspiration (or stock to make it a size blend) never came up. Lo and behold, I finally struck gold with both!

(more context and references under the cut)

Here, I assume Lyanna is living up to the hype of her athleticism comparable to that of a 20-something Maho, despite nearing or being 40. Tyler, as healthy as he is, is a bit more of a strength build than endurance and is getting a quick rest, whereas Lyanna is using the pause to stretch like the yogi she is. Perhaps, she actually decided to commit to the Superhero Circuit finally, and she's training. As for why Ty is using an outdated mp3 player, let's just canonize that he's looking to connect more with his fine wine, bitty boo with some tech that she would've used at his age, or it's just a blocky fitness tracker.

See more of limber Lyanna and tired Tyler in The High Low Life and its corresponding visuals in their gallery here!

Going for That PB ~Autodesk Sketchbook ~Ty on the side ~[Ly flexing on them] "Front view of woman exercising" - Image by Freepik

Circa July 2023.

Given that I gave Ly a canon height of (M [for Maho, her species])-5'10'' (because I love tall smalls), I have no clue if her size to the can is set in our (i.e., you, the viewer, and my) universe, at least whenever that base pic was posted. But I'm pretty sure her size against Tyler's Khadra-tallness is right in that 1:12 range. I hope so.

The real question is, "What kind of magic does their planet Eylea have that allows them to keep pace with each other?" Is it anything like Eywa in Avatar, or is it just vibes and flow?

[kenresearch1]

Top 5 players in US Biosimilar Market

Buy Now

STORY OUTLINE

Pfizer: Excelling in the line of Biosimilar drugs with an experience of more than 10 years with presence in over 180 countries.

Amgen: Making pharmaceutical products with an experience of over 40 years and presence in over 100 countries.

Viartis: Presence in over 165 countries, and making Biosimilar drugs in over 75 markets, this pharmaceutical company is another leading contributor of US Biosimilar market.

Coherus Biosciences: Increasing patient access to cost effective medicines with a Biosimilar drugs experience of 13 years.

Biogen: serving humanity through science with a experiences of more than 40 years in the field of biologics.

According to Ken Research, the US Biosimilar market is anticipated to grow at a CAGR of ~40% in the next five years which currently has a market size of ~USD 9.4 Bn.

The US Biosimilar market is rapidly growing and will be witnessing a significant growth in the next five years.

There are various reasons behind the rapid growth of US Biosimilar market. Some of the major reasons behind the growth of US Biosimilar market include the cost effective nature of Biosimilar drugs, rising geriatric population, rising prevalence of chronic diseases, and growing partnerships between companies to develop Biosimilar drugs.

Various companies and players are contributing to their best efforts in the growth of the US Biosimilar market.

This article aims to put light on the contributions done by the major players towards the growth of the US Biosimilar market.

1.Pfizer

Click to read more about Pfizer

Pfizer is a leading American pharmaceutical company which is operating in the field of generics or original drugs for more than 30 years. But did you know that this pharma not only manufactures biologics but also biosimilar drugs?

Pfizer has been in the business of biosimilar drugs for more than 10 years and have been quite successful as well. With more than 83,000 employees and presence in over 180 countries, this leading pharmaceutical company made almost USD 2 Bn. revenue only from its Biosimilar drugs sale in 2021.

Recently, this pharmaceutical company also collaborated with Samsung in two deals to produce various biosimilar drugs in South Korea. The deal size between these two companies happens to be approximately USD 900 Bn.

The major Biosimilar drugs of this pharmaceutical giant are primarily

ZIRABEV (a Biosimilar of Avastin)

TRAZIMERA (a Biosimilar of Herceptin)

RUXIENCE (a Biosimilar of Rituxan)

RITACRIT (a Biosimilar of Epogen)

NVYEPRIA (a Biosimilar of Neulasta)

NIVESTYM (a Biosimilar of Neupogen)

FILGRASTIM (a Biosimilar of Neupogen).

2.Amgen

Click here to Download a Sample Report

Amgen is another leading American pharmaceutical company which not only makes Biologics or generic drugs but also Biosimilar drugs. This pharmaceutical company has more than 40 years of experience when it comes to pharmaceutical line.

With over 25000 employees and presence in over 100 countries, this pharmaceutical company earned about USD 2 Bn. from their three biosimilar drugs which are reportedly MVASI, KANJITNTI, and AMJEVITA.

This pharma giant has also invested about USD 2 Bn. in the development of Biosimilar drugs.

This pharmaceutical company has made Biosimilar drugs primarily in 4 fields which are General Medicine, Oncology, and Hematology along with, Inflammation.

EPOTEIN ALFA

AMJEVITA

AVSOLA

KANJINTI

MVASI

RIABNI

are the various Biosimilar drugs of Amgen. And, STELARA, EYLEA, SOLIRIS are in their pipeline.

Recently Amgen revealed their Biosimilar report’s 8 version. It revealed a major information which said that the pharmaceutical company saved about USD 10 Bn. through their Biosimilar drugs in the past five years.

3.Viartis

Headquartered in Canonsburg, Pennsylvania, this American pharmaceutical company was founded only in 2020 yet they have achieved massive success in the pharmaceutical products with their revenue being USD 16 ~Bn. in 2022.

With presence in 165 countries and with over 45,000 employees worldwide, this pharmaceutical company makes pharmaceutical products in 10 areas which primarily are Cardiovascular, Dermatology, ophthalmology, Oncology, Gastroenterology, Women’s health, Infectious diseases, Diabetes & Metabolism, Immunology, CNS & Anesthesiology, Respiratory diseases and allergy.

Speaking of their first Biosimilar products, their first ever Biosimilar drug was launched in 2014. They have a variety of Biosimilar drugs which are primarily

TRASTUZUMAB

INSULIN ASPART

PEGFILGRASTIM

INSULIN GLARGINE-YFGN

ADALIMUMAB

BEVACIZUMAB

Their Biosimilar drug Insulin Glargine which is known as SEMGLEE was the first ever interchangeable Biosimilar drug in the United States which was FDA approved.

Their PEGFILGRASTIM also was the first ever FDA approved drug in the United States. They have launched their Biosimilar drugs in over 75 markets worldwide.

4.Coherus Biosciences:

Click here to Ask for a Custom Report

Headquartered in Redwood city, California this American pharmaceutical company earned a revenue of almost USD 211 Mn. In 2022.

With presence in over 55 countries and 300+ employees worldwide, this pharmaceutical company makes products in various areas such as solid tumors, non-small lung cancers, nasopharyngeal carcinoma, small cell lung cancer and hepatocellular carcinoma.

Speaking of their Biosimilar drugs, this pharma has been in the field of creating Biosimilar drugs since 2010 which has given them almost 13 years of experience.

This pharmaceutical company also disclosed that it plans to spend at least USD 1 Tn. on medicines worldwide, out of which at least 40% will be spent on Biosimilar drugs.

Their three major Biosimilar drugs which are also FDA approved include UDENCYA, YUSIMRY, and CIMERLI.

Udencya is a Biosimilar drug of Pegfilgrastim, Yusimry is a Biosimilar drug of Ranibizumab, and Cimerli is a Biosimilar drug of Adalimumab.

5.Biogen

Headquartered in Cambridge, Massachusetts, this American pharmaceutical company earned a revenue of around USD 10 Bn. in 2022.

This company happens to have an experience of more than 40 years when it comes to making pharmaceutical products.

With presence in over 80 countries and more than 9000 employees worldwide, this pharmaceutical company primarily deals in Neurology, Specialized Immunology, Neuropsychiatry, Ophthalmology, and Rare Diseases.

ADUCANUMAB

LECANEMAB

TOFERSEN

ZURANOLONE

LITIFILIMAB

BENAPALI

FLIXABI

IMRALDI

are some of their Biosimilar drugs.

With their Biosimilar drugs, more than 250,000 people have gone on Anti-Tumor Necrosis Factor therapy.

Recently, this pharmaceutical company also made an agreement with Bio-Thera solutions to develop a Biosimilar drug for the treatment of Rheumatoid Arthritis.

[techninja]

The Rise of Gene Therapy: Unveiling Hope in AMD Therapeutics Market

Age-related Macular Degeneration (AMD) is a prevalent eye disorder, particularly in older adults, and it remains a leading cause of vision loss worldwide. The AMD therapeutics market has been a focal point for research and development, with innovations aimed at preventing and treating this debilitating condition. This article explores the current landscape of the AMD therapeutics market, including emerging treatments, market trends, and future prospects.

Understanding AMD:

AMD is a progressive eye disease that affects the macula, the central part of the retina responsible for sharp, central vision. The two main types of AMD are dry (atrophic) and wet (neovascular). Dry AMD is characterized by the gradual breakdown of light-sensitive cells in the macula, while wet AMD involves abnormal blood vessel growth under the macula.

Market Overview:

The AMD therapeutics market has seen significant growth in recent years, driven by factors such as an aging population, increased awareness, and advances in medical technology. Global Market Insights predicts that the AMD therapeutics market will continue to expand, reaching over $11 billion by 2025. Key players in the market include pharmaceutical companies, biotechnology firms, and research institutions.

Emerging Treatments:

1. Anti-VEGF Therapies: Anti-vascular endothelial growth factor (VEGF) therapies have revolutionized the treatment of wet AMD. Drugs like ranibizumab (Lucentis) and aflibercept (Eylea) are administered through regular injections into the eye to inhibit the growth of abnormal blood vessels and prevent further vision loss.

2. Gene Therapy: Gene therapy holds promise for AMD treatment. Clinical trials are underway to develop therapies that can replace or repair faulty genes associated with AMD. This innovative approach has the potential to slow or halt the progression of the disease.

3. Stem Cell Therapies: Stem cell research is exploring the potential of regenerating damaged retinal cells. These therapies aim to replace or repair damaged cells in the macula, offering hope for restoring vision in AMD patients.

4. Complement Inhibitors: The complement system is involved in inflammation and tissue damage in AMD. Inhibitors of this system are being developed to reduce the progression of the disease. Some candidates have shown promise in clinical trials.

Market Trends:

1. Personalized Medicine: Advances in genomics and precision medicine are enabling the development of personalized AMD treatments. Tailoring therapies to an individual's genetic profile may lead to more effective and targeted interventions.

2. Telemedicine: The COVID-19 pandemic accelerated the adoption of telemedicine for AMD diagnosis and management. Remote monitoring and telehealth consultations have become more common, offering convenience and safety for patients.

3. Combination Therapies: Some researchers are exploring the benefits of combining different treatment modalities, such as anti-VEGF drugs with complement inhibitors, to improve treatment outcomes.

4. Patient Education and Advocacy: There is a growing emphasis on educating patients about AMD risk factors and the importance of early detection. Advocacy groups are playing a vital role in raising awareness and promoting research.

Future Prospects:

The AMD therapeutics market is poised for further growth and innovation. As research into AMD continues, we can expect more effective treatments and potentially even a cure. With the aging global population, the demand for AMD therapeutics is likely to increase, driving further investment and research in this field.

In conclusion, the AMD therapeutics market is evolving rapidly, with a focus on innovative treatments, personalized medicine, and telehealth solutions. The journey to finding a cure for AMD is ongoing, but the progress made in recent years is promising. As we continue to unravel the mysteries of this complex disease, the future looks brighter for those affected by AMD, offering hope for improved vision and a better quality of life.

[lindamacdonaldavanir]

Regeneron rebounds to win FDA OK for longer-lasting vision loss drug

Regeneron rebounds to win FDA OK for longer-lasting vision loss drug https://ift.tt/dnDSGbq The agency cleared high-dose Eylea less than two months after rejecting it, and approved a separate Regeneron drug for an ultra-rare disease as well. via BioPharma Dive - Latest News https://ift.tt/GnX6Wbh August 21, 2023 at 08:40AM

[neha24blog]

Age-related Macular Degeneration Market Segmented On The Basis Of Product, Disease Type, Distribution Channel, Region And Forecast 2030: Grand View Research Inc.

San Francisco, 10 Aug 2023: The Report Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease Type (Wet AMD, Dry AMD), By Distribution Channel, By Region, And Segment Forecasts, 2022 – 2030 The global age-related macular degeneration market size is expected to reach USD 17.99 billion by 2030, according to a new study by Grand…

[stress-buster-blog]

alternative eye treatment

Saturday morning I received a letter from the Eye Department at RUH, Bath telling me that my Eylea injections for my wet macular were not going well and that they were proposing an alternative medicine, Vabyismo,  as the team consider it more likely to achieve success.  I will give it a go.  Meanwhile I do have another approach via another method, that of the application of frequencies. I already…

[cgoddardmd]

Getting My Right Eye Monthly Eylea Injection By My Awesome Ophthalmologist @drchunt 2/27/23! Not Too Shabby! 💉👁️😉 (at Columbus, Ohio) https://www.instagram.com/p/CpLAvLWuVV0/?igshid=NGJjMDIxMWI=

[soulpotentialacu]

Two Types of Age-Related Macular Degeneration

Age-related macular degeneration (AMD), is a type of central vision distortion caused by damage to the macular tissue located in the retina at the back of the eye. When central vision is functioning correctly, it is easy to read, drive and identify faces. When this area begins to lose visual clarity, it’s like applying petroleum jelly to the center of the eye, causing distortion in the middle of the field of vision.

AMD is divided into two types: wet (exudative) and dry (atrophic). Dry AMD is the more common form of AMD, occurs in about 85-90% of the AMD population. Dry AMD is less serious than wet AMD. Wet AMD is defined by the appearance of new blood vessels under the retina. These new blood vessels tend to be weak and cause fluid or blood leakage, which can distort vision and lead to retinal damage.1

AMD is caused by the buildup of a yellowish deposit called drusen, a fatty protein. Drusen build up occurs because nutrients are not getting to the eye and waste is not being removed efficiently. Drusen causes a thinning of the macula (the part of the retina located in the back of the eye) due to lack of oxygen to nourish the eye. The macula is responsible for central vision.

An individual can have dry AMD in one eye and wet AMD in the other eye. Approximately 10% of the population with dry AMD later develops wet AMD.

Currently, Western medicine does not have a cure for either wet or dry AMD. Western medicine addresses wet AMD with injections of Vascular Endothelial Growth Factor Inhibitor (VEGF) into the eye. Current VEGF drugs are Avastin, Lucentis, and less commonly, Eylea.1 These drugs bind to VEGF causing it to stop producing blood vessels. Injections are usually a temporary solution and requires multiple injections.1 “An average of seven injections will be required the first year…..and treatment is unlikely to be effective in advanced exudative AMD”.1 “The anti-VEGF drugs only treat the exudative component”.1 Some of these drugs were not initially developed to treat macular degeneration. “Avastin was intended to be given intravenously as an anti-cancer drug”.1

VEGF is a protein in the body which stimulates increased growth of blood vessels. Blood vessels are the result of a lack of oxygen to the eye. VEGF is tasked with getting more blood vessels to an area that is not getting enough oxygen, so the tissue doesn’t die. These additional blood vessels tend to be weak and tear easily which causes them to leak fluid or blood. When these blood vessels leak, they reduce the central field of vision.

Because Western medicine does not have a cure for dry AMD, monitoring the progression of AMD recommending dietary changes, eliminating smoking and supplements are the best they have to offer individuals suffering with AMD.

What can you do?

If you smoke, quit smoking

Change your diet. Drusen, or the fatty protein deposit that builds up in the eye is similar to cholesterol build up in the bloodstream. Eliminate foods that are high in saturated fats and trans fats. Instead of frying or roasting food try grilling, baking or steaming. Increase vegetables and beans in soups and stews and decrease or eliminate meat. Eliminate dairy products and substitute coconut or oat milk instead.2 Consume healthy oils such as coconut and olive oil.

Talk to an acupuncturist specializing in Micro Acupuncture for macular degeneration.

Micro Acupuncture or MA48 originated as AcuNova, a branch of acupuncture that utilizes new points on the hands and feet that are different from other branches of acupuncture. Studies have documented increases in blood flow to the central retinal artery (CAD) which supplies nutrients to the retina following acupuncture.3 Electro-Acupuncture increases blood flow to surrounding nerves.3 Vonda earned her advanced master’s training and certification in the Micro Acupuncture system from Dr. Andy Rosenfarb who has been treating complicated eye conditions with the Micro Acupuncture and the MA48 system with success for more than 15 years. Vonda has successfully helped multiple individuals stabilize their macular degeneration with the Micro Acupuncture protocol. Medical disclaimer: Results may vary from person to person. Testimonials are only to be used as an example of some results not the results guaranteed – not everyone will get the same results outlined in testimonials and text on this page. References

Click here to visit more blogs.